Pregabalin Capsule
Product Images NDC 71335-1744

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71335-1744). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713351744)

Label for Pregabalin Capsules, USP 225 mg by Bryant Ranch Prepack. The label features the drug name, strength (225 mg), and dosage form (capsules). It includes storage instructions, a barcode, and the labeler's logo with the statement "Rx only" and a package count of 30 capsules.*

FDA Label Image

Lbl7133517442

Label for Pregabalin 225 mg (CV) capsule, an oral prescription drug packaged by Bryant Ranch Prepack. The label includes storage instructions (20°-25°C), a barcode, batch lot number, and NDC 71335-1744. It notes a comparison to Lyrica 225 mg capsule by Laurus Labs Limited with a 30-count package size.*

FDA Label Image

Pregabalinchemistrystructure (Pregabalin Chem Structure)

Chemical structure diagram of pregabalin, showing the molecular arrangement of the active ingredient in the product.*

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

A formula depicting creatinine clearance (CLCr) calculation, involving variables age in years, weight in kilograms, serum creatinine in mg/dL, and a factor of 0.85 for female patients. The formula is presented as an equation rather than a graphical plot.*

FDA Label Image

Pregabalinfig1 (Pregabalin Fig 01)

A line graph showing percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. Four lines represent different dosages of Pregabalin (25 mg, 100 mg, 200 mg three times a day) compared to a placebo. The graph illustrates the relationship between pain improvement percentage and proportion of patients reporting improvement for each group.*

FDA Label Image

Pregabalinfig2 (Pregabalin Fig 02)

A line graph comparing percent improvement in pain from baseline (x-axis) with percent of patients improved (y-axis) for Pregabalin 100 mg three times a day versus placebo. The graph shows two curves representing the response rates over a range of pain improvement percentages.*

FDA Label Image

Pregabalinfig3 (Pregabalin Fig 03)

A line graph comparing the percent of patients improved against percent improvement in pain from baseline. It includes four lines representing Pregabalin at doses of 300 mg, 150 mg, and 75 mg taken twice a day, and a placebo group, illustrating trends of patient improvement across these categories.*

FDA Label Image

Pregabalinfig4 (Pregabalin Fig 04)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and Placebo. The graph shows higher improvement percentages with Pregabalin 200 mg and 100 mg compared to placebo across varying levels of pain improvement.*

FDA Label Image

Pregabalinfig5 (Pregabalin Fig 05)

A line graph depicting percent improvement in pain from baseline versus percent of patients improved. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. Percent improvement values range from 0 to 100, with vertical markers at 30 and 50 percent improvement thresholds.*

FDA Label Image

Pregabalinfig6 (Pregabalin Fig 06)

A bar graph depicting responder rates (%) in two studies (E1 and E3) comparing placebo and various doses of a drug. Study E1 shows responder rates for placebo and 150, 300, and 600 mg/day doses, with visible sample sizes. Study E3 compares placebo to 600 mg/day and 600 mg twice daily doses, with corresponding sample sizes. Statistically significant differences versus placebo are noted.*

FDA Label Image

Pregabalinfig7 (Pregabalin Fig 07)

A line graph depicting seizure reduction as median percentage change from baseline plotted against increasing dose (mg/day). The chart compares four studies (E1 BD, E2 TID, E3 BD, E3 TID) with distinct markers, illustrating dose-response relationships and including significant p-values. Placebo baseline is indicated as zero dose.*

FDA Label Image

Pregabalinfig8 (Pregabalin Fig 08)

A line graph showing percent of patients improved on the y-axis against percent improvement in pain from baseline on the x-axis. The graph compares four groups: Pregabalin 600 mg daily dose, 450 mg daily dose, 300 mg daily dose, and placebo, each represented by different line styles, depicting the efficacy of varying dosages in pain improvement.*

FDA Label Image

Pregabalinfig9 (Pregabalin Fig 09)

A Kaplan-Meier survival curve chart comparing the estimated percentage of subjects without LTR over 180 days for Pregabalin versus Placebo. The y-axis shows the estimated percentage of subjects without LTR, ranging from 0% to 100%, and the x-axis shows time in days from 0 to 180. The Pregabalin curve shows a higher estimated survival without LTR than Placebo throughout the period.*

FDA Label Image

Pregabalinfig10 (Pregabalin Fig 10)

A line graph comparing the percent of subjects improved between Pregabalin and Placebo over a range of 0 to 100 percent improvement from baseline to week 12 according to BOCF. The graph shows Pregabalin with a solid line indicating higher improvement percentages, decreasing from around 58% to 0%, and Placebo with a dashed line showing lower improvement percentages, decreasing from about 27% to 0%.*

FDA Label Image

Pregabalinfig11 (Pregabalin Fig 11)

A line graph comparing the percentage of subjects improved over different levels of improvement from baseline to week 16 between Pregabalin and placebo groups. The x-axis represents percent improved from baseline to week 16, and the y-axis represents the percent of subjects improved. Pregabalin shows consistently higher percentages of subjects improved compared to placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.